Celltrion Pharm’s liver disease drug could lose insurance benefits

Celltrion Pharm Godex Cap Prescription Liver Disease Treatment. could lose his reimbursement because the Health Insurance Review and Assessment Service (HIRA) recently decided to withdraw his insurance benefits. The company immediately appealed the decision.

HIRA released the results of the Drug Reimbursement Review Committee meeting on Thursday.

Celltrion Pharm Godex Cap Liver Disease Treatment. runs the risk of losing their refund.

After reassessing the reimbursable drugs for 2022, the committee concluded that Godex Cap. (combination of six agents plus adenine hydrochloride) was not eligible for reimbursement.

Earlier in March, HIRA placed six drugs, including Godex Cap. of Celltrion Pharm, on the list of reimbursed drugs for 2022.

Godex treats liver disease with elevated glutamic-pyruvic transaminase (SGPT). Outpatient prescriptions for the drug reached 74.7 billion won ($57.3 million) in 2021.

If Godex loses reimbursement, Celltrion Pharm will have to suffer a reduction in prescriptions from Godex.

Celltrion Pharm has 30 days to appeal HIRA’s decision. If the company appeals, the Drug Reimbursement Review Committee determines whether to remove reimbursement again.

Following HIRA’s announcement, Celltrion Pharm issued a statement and notified its position.

“HIRA announced the first result of the re-evaluation indicating that the drug was not eligible for insurance benefits. But this is not the final result. We will complete the data and submit an appeal as soon as possible,” said Celltrion Pharm.

Godex has proven its effectiveness in liver disease through various investigator-initiated trials since gaining marketing approval in 2002, the company said.

Last year, the drug was prescribed to about 480,000 patients in Korea as one of the representative treatments for liver disease in Korea.

Based on the efficacy data, Celltrion Pharm will sufficiently discuss with HIRA and the Department of Health and Welfare during the objection period and actively explain the company’s position, the company said.

“We will do everything we can to keep drug reimbursement in the bottom line and help promote public health,” he said.

On the same day, HIRA also concluded that drugs using streptokinase and streptodornase as ingredients were not eligible for reimbursement. These drugs include Mucotase tab from Hanmi Pharmaceutical, Skidase tab from Kyongbo Pharm, and Varidase tab from SK Chemicals.